Thrombocythemia, Essential
"Thrombocythemia, Essential" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.
MeSH Number(s)
C15.378.100.832
C15.378.140.860.800
C15.378.190.636.860.800
C15.378.463.825
Concept/Terms
Thrombocythemia, Essential- Thrombocythemia, Essential
- Essential Thrombocythemia
- Essential Thrombocythemias
- Thrombocythemias, Essential
- Thrombocythemia, Primary
- Primary Thrombocythemia
- Primary Thrombocythemias
- Thrombocythemias, Primary
- Thrombocythemia, Idiopathic
- Idiopathic Thrombocythemia
- Idiopathic Thrombocythemias
- Thrombocythemias, Idiopathic
- Hemorrhagic Thrombocythemia
- Thrombocythemia, Hemorrhagic
- Hemorrhagic Thrombocythemias
- Thrombocythemias, Hemorrhagic
Below are MeSH descriptors whose meaning is more general than "Thrombocythemia, Essential".
Below are MeSH descriptors whose meaning is more specific than "Thrombocythemia, Essential".
This graph shows the total number of publications written about "Thrombocythemia, Essential" by people in Harvard Catalyst Profiles by year, and whether "Thrombocythemia, Essential" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 3 | 0 | 3 |
| 2007 | 0 | 2 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 3 | 0 | 3 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 3 | 1 | 4 |
| 2017 | 1 | 1 | 2 |
| 2018 | 2 | 0 | 2 |
| 2019 | 3 | 0 | 3 |
| 2020 | 5 | 0 | 5 |
| 2021 | 3 | 0 | 3 |
Below are the most recent publications written about "Thrombocythemia, Essential" by people in Profiles.
-
PD-1 inhibition in advanced myeloproliferative neoplasms. Blood Adv. 2021 12 14; 5(23):5086-5097.
-
Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera. Curr Hematol Malig Rep. 2021 10; 16(5):473-482.
-
Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms. Clin Cancer Res. 2021 10 15; 27(20):5708-5717.
-
Hematopoietic expression of a chimeric murine-human CALR oncoprotein allows the assessment of anti-CALR antibody immunotherapies in vivo. Am J Hematol. 2021 06 01; 96(6):698-707.
-
MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT. Probl Radiac Med Radiobiol. 2020 Dec; 25:362-373.
-
Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis. Ann Hematol. 2021 Jan; 100(1):105-116.
-
Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. Leuk Res. 2020 11; 98:106459.
-
Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis. Leukemia. 2021 06; 35(6):1643-1660.
-
A Practical Guide for Using Myelofibrosis Prognostic Models in the Clinic. J Natl Compr Canc Netw. 2020 09; 18(9):1271-1278.
-
Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms. Cancer Med. 2020 03; 9(6):2039-2051.